文献速递脊柱关节炎

银屑病关节炎靶向治疗原发失败的发生率与预测因素

Incidence and predictors of primary failure of targeted therapy in patients with Psoriatic Arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2025-10-27

在591例接受靶向DMARDs治疗的银屑病关节炎患者中,209例(35.4%)发生原发失败。校正日历时间后,每日饮酒(OR 3.57,95%CI 1.32-9.6)和较高BMI(OR 1.04,95%CI 1.01-1.08)与原发失败相关,而较高教育程度(OR 0.45,95%CI 0.26-0.78)、基线SJC≥5(OR 0.45,95%CI 0.25-0.80)和较高损伤关节计数(OR 0.96,95%CI 0.93-0.995)与风险降低相关。

要点

  • 591例接受靶向DMARDs的PsA患者中,209例(35.4%)发生原发失败。
  • 每日饮酒(OR 3.57)和较高BMI(OR 1.04)与原发失败风险升高相关。
  • 较高教育程度、基线SJC≥5和较高损伤关节计数与原发失败风险降低相关。

核心结论

  • 靶向DMARDs原发失败在银屑病关节炎中常见,可能受社会经济和疾病相关特征影响。

研究设计与样本

  • 前瞻性观察性队列研究,纳入591例接受靶向DMARDs(生物制剂或合成制剂)治疗的银屑病关节炎患者。
  • 原发失败定义为治疗第一年内医生判断无效,或一年访视时未达到基线肿胀关节计数(SJC)降低≥40%且PASI降低≥50%(前提是治疗后PASI>2)。
  • 比较原发失败患者与应答者及因非疗效原因停药的患者,采用单变量和多变量多项逻辑回归,校正日历时间。

主要发现

  • 591例患者中209例(35.4%)发生原发失败。
  • 多变量模型校正日历时间后,每日饮酒(OR 3.57,95%CI 1.32-9.6)和较高BMI(OR 1.04,95%CI 1.01-1.08)与原发失败发生相关。
  • 较高教育程度(OR 0.45,95%CI 0.26-0.78)、基线SJC≥5(OR 0.45,95%CI 0.25-0.80)和较高损伤关节计数(OR 0.96,95%CI 0.93-0.995)与原发失败风险降低相关。

关键数值与推荐

  • 原发失败定义:治疗第一年内医生判断无效,或一年访视时未达到基线SJC降低≥40%且PASI降低≥50%(前提是治疗后PASI>2)。
  • 每日饮酒:OR 3.57,95%CI 1.32-9.6。
  • 较高BMI:OR 1.04,95%CI 1.01-1.08。
  • 较高教育程度:OR 0.45,95%CI 0.26-0.78。
  • 基线SJC≥5:OR 0.45,95%CI 0.25-0.80;较高损伤关节计数:OR 0.96,95%CI 0.93-0.995。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primary failure of targeted DMARDs (biologic or synthetic) is common in rheumatologic practice. We aimed to define the incidence of primary failure in patients with psoriatic arthritis (PsA) and identify the factors associated with its occurrence. METHODS: We included patients with PsA followed at our prospective observational cohort. We defined primary failure as either the physician's judgment of ineffectiveness during the first year of therapy or failure, at the one-year visit, to achieve ≥40 % reduction in baseline swollen joint count (SJC) and ≥50 % reduction in PASI (provided that PASI was >2 after therapy). We identified patients with primary failure of targeted DMARDs and compared them to responders and patients who discontinued treatment for reasons not related to effectiveness. We used univariable and multivariable multinomial logistic regression, adjusted for calendar time, to model the effect of each variable on the outcome. RESULTS: Among 591 patients on targeted DMARDs, 209 (35.4 %) experienced primary failure. In the multivariable model, adjusted for calendar time, daily alcohol consumption (OR 3.57, 95 % CI 0.1.32-9.6) and higher BMI (OR 1.04, 95 % CI 1.01, 1.08) were associated with the development of primary failure. In contrast, higher educational attainment (OR 0.45, 95 % CI 0.26-0.78]), SJC ≥5 at baseline (OR 0.45, 95 % CI 0.25-0.80), and a higher damaged joint count (OR 0.96, 95 % CI 0.93, 0.995) were associated with a reduced risk of primary failure. CONCLUSION: Primary failure of targeted DMARDs is common in PsA and may be influenced by socioeconomic and disease-related features.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kharouf F, Gao S, AlHadri A, et al. Incidence and predictors of primary failure of targeted therapy in patients with Psoriatic Arthritis. Semin Arthritis Rheum. 2025. PMID: 41176842. doi:10.1016/j.semarthrit.2025.152859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。